Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hypersensitivity Reaction
  Free Subscription

Articles published in
J Am Acad Dermatol
    May 2024
  1. ELSTON DM
    This month in JAAD: May 2024.
    J Am Acad Dermatol. 2024;90:930.
    >> Share

  2. SILVERBERG JI, Kirsner RS, Margolis DJ, Tharp M, et al
    Efficacy and safety of crisaborole ointment, 2%, in participants aged >/=45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
    J Am Acad Dermatol. 2024;90:945-952.
    >> Share

  3. ZHANG L, Li X, Xu X, Le Y, et al
    Ixekizumab-induced urticaria is associated with the short duration of remission in psoriasis by activation of mast cells.
    J Am Acad Dermatol. 2024;90:970-976.
    >> Share

  4. SAKUNCHOTPANIT G, Rohan TZ, Milosavljevic S, Patil MK, et al
    Procalcitonin: A potentially useful serum test in patients with dermatologic disease.
    J Am Acad Dermatol. 2024;90:1090-1091.
    >> Share

  5. WOHLTMANN WE
    JAAD Game Changer: Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients.
    J Am Acad Dermatol. 2024;90:1114.
    >> Share

    April 2024
  6. LEIBOWITZ R, Fischer A, Collins LF, Feldman RJ, et al
    HIV-related exclusion criteria in atopic dermatitis and prurigo nodularis clinical trials.
    J Am Acad Dermatol. 2024 Apr 12:S0190-9622(24)00633.
    >> Share

  7. HASAN I, Parsons L, Duran S, Zinn Z, et al
    Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.
    J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00566.
    >> Share

  8. POWERS CM, Piontkowski AJ, Orloff J, Pulsinelli J, et al
    Risk of lymphoma in patients with atopic dermatitis: A case-control study in the All of Us database.
    J Am Acad Dermatol. 2024 Apr 4:S0190-9622(24)00554.
    >> Share

    March 2024
  9. MANZAR D, Suntres E, Nair N, Patel Y, et al
    Elevation of Creatine Phosphokinase in Moderate-Severe Atopic Dermatitis is Associated with the use of JAK inhibitors but not Dupilumab: A Systematic Review and Meta-Analysis.
    J Am Acad Dermatol. 2024 Mar 28:S0190-9622(24)00538.
    >> Share

  10. HREN MG, Guenin S, Khattri S
    Successful use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease.
    J Am Acad Dermatol. 2024 Mar 15:S0190-9622(24)00492.
    >> Share

  11. MARTINEZ-CABRIALES S, Coulombe J, Aaron M, Hussain SH, et al
    Preliminary summary and reclassification of cases from the Pediatric Research of Management in Stevens-Johnson syndrome and Epidermonecrolysis (PROMISE) study: A North American, multisite retrospective cohort.
    J Am Acad Dermatol. 2024;90:635-637.
    >> Share

  12. EBATA A, Ogawa-Momohara M, Fukaura R, Yamashita Y, et al
    Increased Janus kinase activation in cutaneous vasculitis.
    J Am Acad Dermatol. 2024;90:627-629.
    >> Share

    February 2024
  13. AFVARI S, Zippin JH
    Photodermatoses in patients with atopic dermatitis: A 10-year retrospective cohort study.
    J Am Acad Dermatol. 2024 Feb 17:S0190-9622(24)00132.
    >> Share

  14. MA EZ, Hooper SR, Seegan PL, Wan J, et al
    Association of atopic dermatitis with emotional and behavioral problems in childhood.
    J Am Acad Dermatol. 2024 Feb 4:S0190-9622(24)00242.
    >> Share

  15. WU CY, Wu CY, Li MC, Ho HJ, et al
    Association of Air Quality Index (AQI) with incidence of atopic dermatitis in Taiwan: A nationwide population-based cohort Study.
    J Am Acad Dermatol. 2024 Feb 2:S0190-9622(24)00207.
    >> Share

  16. WATANABE Y, Watanabe T, Yamaguchi Y
    Anti-SS-A antibody is a potential predictor of severe Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study.
    J Am Acad Dermatol. 2024;90:385-387.
    >> Share

    January 2024
  17. LEFEVRE MA, Nosbaum A, Mosnier A, Lenief V, et al
    Gene profiling in active dermatitis lesions strengthens the diagnosis of allergic contact dermatitis.
    J Am Acad Dermatol. 2024 Jan 10:S0190-9622(24)00059.
    >> Share

  18. SHAH SA, Mitra N, Margolis DJ, Wan J, et al
    Heterogeneity in cutaneous infection prevalence and frequency by timing of childhood atopic dermatitis onset.
    J Am Acad Dermatol. 2024 Jan 9:S0190-9622(24)00055.
    >> Share

  19. AVALLONE G, Mastorino L, Tavoletti G, Macagno N, et al
    Clinical outcomes and management of JAK inhibitor-associated acne (JAKne) in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.
    J Am Acad Dermatol. 2024 Jan 8:S0190-9622(24)00049.
    >> Share

  20. HEYMANN WR
    Atopic Dermatitis: The Perpetual Need for Science and Art.
    J Am Acad Dermatol. 2024 Jan 6:S0190-9622(24)00021.
    >> Share

    December 2023
  21. MEROLA JF, Ertmer B, Liang H, Yue X, et al
    Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data.
    J Am Acad Dermatol. 2023 Dec 24:S0190-9622(23)03400.
    >> Share

  22. KANTOR J
    This Month in JAAD International: February 2024: Atopic Dermatitis and diabetes.
    J Am Acad Dermatol. 2023 Dec 5:S0190-9622(23)03268.
    >> Share

    November 2023
  23. CRAVER AE, Chen GF, Cohen JM
    Association between Atopic Dermatitis and Hypertension and Hyperlipidemia: A Cross-Sectional Study in the All of Us Research Program.
    J Am Acad Dermatol. 2023 Nov 24:S0190-9622(23)03226.
    >> Share

  24. CHIESA FUXENCH ZC, Mitra N, Del Pozo D, Hoffstad O, et al
    Risk of Atopic Dermatitis and the atopic march paradigm in children of mothers with atopic illnesses: a birth cohort study from the United Kingdom.
    J Am Acad Dermatol. 2023 Nov 18:S0190-9622(23)03213.
    >> Share

  25. DAVIS DMR, Drucker AM, Alikhan A, Bercovitch L, et al
    Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
    J Am Acad Dermatol. 2023 Nov 3:S0190-9622(23)02879.
    >> Share

  26. DAVIS DMR, Drucker AM, Alikhan A, Bercovitch L, et al
    Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
    J Am Acad Dermatol. 2023 Nov 3:S0190-9622(23)02878.
    >> Share

  27. FISHBEIN AB, Mukherji J, Demczuk M, Buranosky B, et al
    Biomarkers of Response to Topical Crisaborole in Mild/Moderate Pediatric Atopic Dermatitis Patients From Minimally Invasive Tape Strip Transcriptome.
    J Am Acad Dermatol. 2023 Nov 2:S0190-9622(23)03110.
    >> Share

    October 2023
  28. REEDER MJ, Zhang D, Aravamuthan SR, Warshaw EM, et al
    More than Just MI: Retrospective Analysis of Patients with Isothiazolinone Allergy in North America, 2017-2020.
    J Am Acad Dermatol. 2023 Oct 23:S0190-9622(23)03035.
    >> Share

  29. BOCQUEL S, Soria A, Raison-Peyron N, Badaoui A, et al
    Impact of dupilumab on patch-test results and allergic contact dermatitis: A prospective multicenter study.
    J Am Acad Dermatol. 2023 Oct 21:S0190-9622(23)03032.
    >> Share

  30. DIAZ MJ, Haq Z, Abdi P, Tran JT, et al
    Association between alopecia areata and atopic dermatitis: a nested case-control study of the All of Us database.
    J Am Acad Dermatol. 2023 Oct 21:S0190-9622(23)03034.
    >> Share

  31. VEVERKA KA, Thng STG, Silverberg JI, Armstrong AW, et al
    Safety and efficacy of eblasakimab, an IL-13Ralpha1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study.
    J Am Acad Dermatol. 2023 Oct 20:S0190-9622(23)03029.
    >> Share

  32. SCHMARTZ S, Welfringer-Morin A, Le Bourgeois M, Delacourt C, et al
    Respiratory complications in pediatric epidermal necrolysis: A retrospective study of 22 cases.
    J Am Acad Dermatol. 2023;89:857-859.
    >> Share

  33. REDDY S, Yi L, Shields B, Platts-Mills T, et al
    Alpha-gal syndrome: A review for the dermatologist.
    J Am Acad Dermatol. 2023;89:750-757.
    >> Share

    September 2023
  34. PALLER AS, Siegfried E, Marron SE, Clark M, et al
    Development and validation of a caregiver-reported Numeric Rating Scale for measuring worst scratch/itch in patients aged 6 months to younger than 6 years with atopic dermatitis.
    J Am Acad Dermatol. 2023 Sep 29:S0190-9622(23)02880.
    >> Share

  35. CHEN YW, Chen HH, Huang WN, Hsu CY, et al
    Dupilumab alleviates pruritus regardless of skin improvement in adults with atopic dermatitis: a cohort study.
    J Am Acad Dermatol. 2023 Sep 24:S0190-9622(23)02858.
    >> Share

  36. BRODELL RT
    JAAD Game Changers: Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study.
    J Am Acad Dermatol. 2023 Sep 22:S0190-9622(23)02851.
    >> Share

  37. WOHLTMANN W
    JAAD Game Changers: Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: Real-world evidence.
    J Am Acad Dermatol. 2023 Sep 15:S0190-9622(23)02731.
    >> Share

  38. OTT H, Abraham S, Kind B, Haufe E, et al
    Comment on: "Interim results from the PEDISTAD Real-World Registry by Paller et al. " - First results from the German TREATkids registry for children and adolescents with moderate to severe atopic dermatitis (AD).
    J Am Acad Dermatol. 2023 Sep 15:S0190-9622(23)02780.
    >> Share

  39. ISAQ NA, Link J
    Response to Papp et al.'s "Long-Term Safety and Disease Control with Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies".
    J Am Acad Dermatol. 2023 Sep 12:S0190-9622(23)02695.
    >> Share

  40. XU L, Sockler PG, Park G, Grossberg AL, et al
    Characterization of patient portal messaging use and content among a pediatric atopic dermatitis population: a cross-sectional study.
    J Am Acad Dermatol. 2023 Sep 11:S0190-9622(23)02687.
    >> Share

  41. BRODELL RT
    JAAD Game Changers: Relative efficacy of systemic treatments for atopic dermatitis.
    J Am Acad Dermatol. 2023 Sep 7:S0190-9622(23)02675.
    >> Share

  42. GRANT-KELS JM
    JAAD Game Changers: Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.
    J Am Acad Dermatol. 2023 Sep 7:S0190-9622(23)02672.
    >> Share

  43. SORENSEN R
    JAAD Game Changers: Assessment of major comorbidities in adults with atopic dermatitis using the Charlson comorbidity index.
    J Am Acad Dermatol. 2023 Sep 2:S0190-9622(23)02656.
    >> Share

  44. WALLS AC, Faletsky A, Chu B, Micheletti RG, et al
    Epidemiology and diagnostic classification of adults presenting with an initial episode of leukocytoclastic vasculitis: A multicenter review of 440 patients.
    J Am Acad Dermatol. 2023;89:582-584.
    >> Share

  45. FILLEY AR, Woodruff CM
    The Modernization of Cosmetics Regulation Act of 2022: What dermatologists need to know.
    J Am Acad Dermatol. 2023;89:629-631.
    >> Share

    August 2023
  46. GEORGAKOPOULOS JR, Sheka D, Rankin B, Maliyar K, et al
    Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: a multicenter retrospective study.
    J Am Acad Dermatol. 2023 Aug 28:S0190-9622(23)02645.
    >> Share

  47. SORENSEN R
    Autoimmune diseases in adults with atopic dermatitis.
    J Am Acad Dermatol. 2023 Aug 26:S0190-9622(23)02632.
    >> Share

  48. JACKSON JM, Althoff A, Rasouliyan L, Long S, et al
    Cardiovascular comorbidities in atopic dermatitis: potential implications for use of JAK inhibitors.
    J Am Acad Dermatol. 2023 Aug 19:S0190-9622(23)02563.
    >> Share

  49. SCHNEEWEISS MC, Richard Wyss, Schneeweiss S, Anand P, et al
    Joint pain in patients with atopic dermatitis receiving treatment with dupilumab: a US nation-wide cohort study.
    J Am Acad Dermatol. 2023 Aug 19:S0190-9622(23)02518.
    >> Share

  50. FRIEDMAN A
    Cause-specific mortality in adults with atopic dermatitis.
    J Am Acad Dermatol. 2023 Aug 17:S0190-9622(23)02505.
    >> Share

  51. PETTY AJ, Emge DA, Blanchard SK, Selim MA, et al
    Pilot, open-label, single-arm clinical trial evaluating the efficacy of topical crisaborole for steroid refractory morphea.
    J Am Acad Dermatol. 2023;89:390-392.
    >> Share

  52. MCSWEENEY SM, Christou EAA, Maurer M, Grattan CE, et al
    Physical urticaria: Clinical features, pathogenesis, diagnostic work-up, and management.
    J Am Acad Dermatol. 2023;89:324-337.
    >> Share

  53. SOOD S, Heung M, Georgakopoulos JR, Mufti A, et al
    Use of Janus kinase inhibitors for granulomatous dermatoses: A systematic review.
    J Am Acad Dermatol. 2023;89:357-359.
    >> Share

  54. RUTHERFORD A, Erickson S, Keimig E, Wickless HW, et al
    Fibrosing vasculitides: A heuristic for investigation.
    J Am Acad Dermatol. 2023;89:e71-e74.
    >> Share

    July 2023
  55. JOHNSON H, Aquino MR, Snyder A, Collis RW, et al
    Prevalence of allergic contact dermatitis in children with and without atopic dermatitis: A multicenter retrospective case-control study.
    J Am Acad Dermatol. 2023 Jul 29:S0190-9622(23)01270.
    >> Share

  56. LEE SS, Kaushik A, Natsis N, Kusari A, et al
    A multimodal initiative improves general pediatric provider management of atopic dermatitis in children: A prospective interventional study.
    J Am Acad Dermatol. 2023 Jul 28:S0190-9622(23)00711.
    >> Share

  57. WEI BM, Fox LP, Kaffenberger BH, Korman AM, et al
    Drug-induced Hypersensitivity Syndrome / Drug Reaction with Eosinophilia and Systemic Symptoms. Part I. Epidemiology, Pathogenesis, Clinicopathological Features, and Prognosis.
    J Am Acad Dermatol. 2023 Jul 27:S0190-9622(23)02402.
    >> Share

  58. WEI BM, Fox LP, Kaffenberger BH, Korman AM, et al
    Drug-induced Hypersensitivity Syndrome / Drug Reaction with Eosinophilia and Systemic Symptoms. Part II. Diagnosis and Management.
    J Am Acad Dermatol. 2023 Jul 27:S0190-9622(23)02403.
    >> Share

  59. JOSHI TP, Bancroft A, DeLeon D, Garcia D, et al
    Association of Atopic Dermatitis with Substance Use Disorders: A Case-Control Study in the All of Us Research Program.
    J Am Acad Dermatol. 2023 Jul 14:S0190-9622(23)01361.
    >> Share

  60. GONG T, Zhang P, Ruan SF, Xiao Z, et al
    APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts.
    J Am Acad Dermatol. 2023;89:45-52.
    >> Share

  61. MCSWEENEY SM, Kloczko E, Chadha M, Sarkany R, et al
    Systematic review of the clinical characteristics and natural history of solar urticaria.
    J Am Acad Dermatol. 2023;89:138-140.
    >> Share

    June 2023
  62. SMITH B, Engel P, Javadi SS, Han G, et al
    Reply to "Association of Atopic Dermatitis with Graves' Disease and Hashimoto's Thyroiditis: A Case-Control Study in the All of Us Research Program".
    J Am Acad Dermatol. 2023 Jun 12:S0190-9622(23)01103.
    >> Share

  63. JOSHI TP, Bancroft A, Garcia D, Kahla JA, et al
    Association of Atopic Dermatitis with Graves' Disease and Hashimoto's Thyroiditis: A Case-Control Study in the All of Us Research Program.
    J Am Acad Dermatol. 2023 Jun 12:S0190-9622(23)01104.
    >> Share

  64. TONG Z, Zhang Y, Zhou K, Zou Y, et al
    An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab.
    J Am Acad Dermatol. 2023 Jun 10:S0190-9622(23)01083.
    >> Share

  65. SHIELDS A, Yoon J, Barbieri JS
    Content Analysis of Health-Related Quality-of-Life Patient Reported Outcome Measures Used in Patients with Atopic Dermatitis.
    J Am Acad Dermatol. 2023 Jun 7:S0190-9622(23)01013.
    >> Share

  66. JOSHI I, Maczuga S, Flamm A
    Examining Occupational Characteristics of Patients with Allergic Contact Dermatitis: A Retrospective Claims- Based Analysis.
    J Am Acad Dermatol. 2023 Jun 1:S0190-9622(23)01000.
    >> Share

  67. BOWIE AC, Tadrous M, Thiruchelvam D, Ivers NM, et al
    A comparison of family physician and dermatologist topical corticosteroid prescriptions: A population-based cross-sectional study.
    J Am Acad Dermatol. 2023;88:1291-1299.
    >> Share

  68. GINZBURG A, Agrawal S
    Microfoam plaster application at forehead to prevent postoperative eyelid edema in patients after hair transplantation.
    J Am Acad Dermatol. 2023;88:e299-e300.
    >> Share

    May 2023
  69. SCARBERRY KB, Mahlberg SJ, Nedorost S
    Trends in Positive Patch Tests to Formaldehyde-Containing Allergens Found in Personal Care Products.
    J Am Acad Dermatol. 2023 May 29:S0190-9622(23)00989.
    >> Share

  70. KO MJ, Tsai WC, Tsai PH, Hsu LY, et al
    Ultraviolet B Phototherapy Does Not Increase the Risk of Skin Cancer Among Patients with Atopic Dermatitis: A Population-Based Retrospective Cohort Study.
    J Am Acad Dermatol. 2023 May 24:S0190-9622(23)00977.
    >> Share

  71. BLAUVELT A, Ladizinski B, Prajapati VH, Laquer V, et al
    Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
    J Am Acad Dermatol. 2023 May 23:S0190-9622(23)00966.
    >> Share

  72. SMITH B, Engel P, Javadi SS, Han G, et al
    Association between atopic dermatitis and cardiovascular disease in a nationally representative United States population.
    J Am Acad Dermatol. 2023 May 22:S0190-9622(23)00967.
    >> Share

  73. O'HAGAN R, Caldas SA, Correa da Rosa JM, Guttman-Yassky E, et al
    The impact of atopic dermatitis on alopecia areata: A two-sample Mendelian randomization study.
    J Am Acad Dermatol. 2023 May 17:S0190-9622(23)00907.
    >> Share

  74. CHIRICOZZI A, Balato A, Fabbrocini G, Di Nardo L, et al
    Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study.
    J Am Acad Dermatol. 2023 May 9:S0190-9622(23)00765.
    >> Share

  75. LABIB A, Ju T, Yosipovitch G
    Emerging Treatments for Itch in Atopic Dermatitis: A Review.
    J Am Acad Dermatol. 2023 May 6:S0190-9622(23)00761.
    >> Share

  76. PEZZOLO E, Gambardella A, Guanti M, Bianchelli T, et al
    Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: a multicenter, prospective, open-label case series study.
    J Am Acad Dermatol. 2023 May 5:S0190-9622(23)00760.
    >> Share

  77. SILVERBERG JI, Simpson B, Abuabara K, Guttman-Yassky E, et al
    Prevalence and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: A Cross Sectional Study from the TARGET-DERM AD Cohort.
    J Am Acad Dermatol. 2023 May 5:S0190-9622(23)00756.
    >> Share

  78. SMITH JH, Silverberg JI
    Correlation of clinician-reported outcomes with patient-reported outcomes by race and ethnicity in patients with atopic dermatitis.
    J Am Acad Dermatol. 2023 May 4:S0190-9622(23)00754.
    >> Share

  79. HEYMANN WR
    Searching for a T-cell glitch in Gleich syndrome.
    J Am Acad Dermatol. 2023;88:1006-1007.
    >> Share

  80. SINGH K, Valido K, Swallow M, Okifo KO, et al
    Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis.
    J Am Acad Dermatol. 2023;88:1094-1100.
    >> Share

  81. CHEN JY, Yiannias JA, Davis MDP, Yang YW, et al
    Evaluating the utility of screening corticosteroids found in standard/baseline patch testing series.
    J Am Acad Dermatol. 2023;88:1173-1175.
    >> Share

  82. GALLARDO MA, Mallela T, Gilkey T, Himed S, et al
    Demographic and laboratory differences seen between acute generalized exanthematous pustulosis and drug reaction with eosinophilia and systemic symptoms: A cross-sectional analysis.
    J Am Acad Dermatol. 2023;88:1142-1145.
    >> Share

  83. MILANI-NEJAD N, Trinidad J, Kaffenberger BH
    Acute kidney injury in vancomycin-induced drug reaction with eosinophilia and systemic symptoms: A case-control study.
    J Am Acad Dermatol. 2023;88:1121-1123.
    >> Share

  84. MORGADO-CARRASCO D, Giacaman-Von der Weth M, Fusta-Novell X, Podlipnik S, et al
    Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab.
    J Am Acad Dermatol. 2023;88:1110-1111.
    >> Share

  85. NEILL BC, Dallo C, Rajpara A, Liu D, et al
    Use of the back of the hands to apply ointment.
    J Am Acad Dermatol. 2023;88:e187.
    >> Share

  86. ABISROR N, Mekinian A, Dechartres A, Groh M, et al
    Abnormal T-cell phenotype in episodic angioedema with hypereosinophilia (Gleich syndrome): Frequency, clinical implication, and prognosis.
    J Am Acad Dermatol. 2023;88:e243-e250.
    >> Share

    April 2023
  87. STEFANKO NS, Quan VL, Chovatiya R
    Efficacy, Safety, and Treatment Patterns of Ruxolitinib 1.5% Cream in Adult Atopic Dermatitis: A Single Center Retrospective Study.
    J Am Acad Dermatol. 2023 Apr 22:S0190-9622(23)00727.
    >> Share

  88. YEUNG J, Gooderham MJ, Hong HC, Lynde C, et al
    Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspective.
    J Am Acad Dermatol. 2023 Apr 19:S0190-9622(23)00520.
    >> Share

  89. KIM M, Del Duca E, Cheng J, Carroll B, et al
    Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome towards nonlesional and normal skin.
    J Am Acad Dermatol. 2023 Apr 11:S0190-9622(23)00542.
    >> Share

  90. YOUNG K, Collis RW, Sheinbein D, Shope C, et al
    Retrospective review of pediatric patch testing results in skin of color.
    J Am Acad Dermatol. 2023;88:953-954.
    >> Share

  91. HUNG YT, Chen YW, Huang Y, Lin YJ, et al
    Acute graft-versus-host disease presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study.
    J Am Acad Dermatol. 2023;88:792-801.
    >> Share

    March 2023
  92. KANTOR J
    This Month in JAAD International: May 2023: Air pollution and atopic dermatitis.
    J Am Acad Dermatol. 2023 Mar 14:S0190-9622(23)00372.
    >> Share

  93. SCHODER K, Zhu Y, Schneeweiss S, Merola J, et al
    Use of systemic immunomodulating medications in pregnant women with atopic dermatitis: a nationwide US study.
    J Am Acad Dermatol. 2023 Mar 9:S0190-9622(23)00358.
    >> Share

  94. WALLACE EB, Khosravi H, Joyce CJ, Vleugels FR, et al
    Examining the epidemiology of coincident psoriasis and sarcoidosis: An observational cross-sectional study.
    J Am Acad Dermatol. 2023;88:661-663.
    >> Share

  95. NEILL BC, Willis CD, Neill JA, Hanson C, et al
    Treating isotretinoin-associated cheilitis with hydrocortisone-containing lip balm.
    J Am Acad Dermatol. 2023;88:e113.
    >> Share

    February 2023
  96. SMITH B, Engel P, Collier MR, Devjani S, et al
    Association between electronic-cigarette use and atopic dermatitis among United States adults.
    J Am Acad Dermatol. 2023 Feb 25:S0190-9622(23)00280.
    >> Share

  97. SHI VY, Chamberlain W, Siegfried E, Kraff-Cooper C, et al
    Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: A review.
    J Am Acad Dermatol. 2023 Feb 15:S0190-9622(23)00196.
    >> Share

  98. QIAN MF, Li S, Honari G, Sarin KY, et al
    Prevalence of allergic contact dermatitis following patch testing in patients with atopic dermatitis: a retrospective United States claims-based study.
    J Am Acad Dermatol. 2023 Feb 10:S0190-9622(23)00178.
    >> Share

  99. DEL DUCA E, Renert-Yuval Y, Pavel AB, Mikhaylov D, et al
    Proteomic characterization of atopic dermatitis blood from infancy to adulthood.
    J Am Acad Dermatol. 2023 Feb 9:S0190-9622(23)00172.
    >> Share

  100. BAILEY K, Adamson AS
    Health care disparities and dermatology: A duty to delve deeper.
    J Am Acad Dermatol. 2023;88:e107-e108.
    >> Share

  101. FISHBEIN AB, Lor J, Penedo FJ, Forrest CB, et al
    Patient-reported outcomes for measuring sleep disturbance in pediatric atopic dermatitis: Cross-sectional study of the Patient Reported Outcomes Measurement Information System pediatric sleep measures and actigraphy.
    J Am Acad Dermatol. 2023;88:348-356.
    >> Share

  102. SINGH P, Silverberg JI
    Outpatient utilization patterns for atopic dermatitis in the United States.
    J Am Acad Dermatol. 2023;88:357-363.
    >> Share

  103. DUAN GY, Silverberg JI
    Sleep impairment in patients with chronic inflammatory skin diseases: A review of mechanisms and management.
    J Am Acad Dermatol. 2023;88:421-427.
    >> Share

    January 2023
  104. YILDIRIM AM, Pradhan T, Zinn ZA
    Dupilumab treatment for atopic dermatitis is associated with decreased utilization of psychostimulants for attention deficit hyperactivity disorder: a retrospective cohort study.
    J Am Acad Dermatol. 2023 Jan 31:S0190-9622(23)00159.
    >> Share

  105. YOUNG K, Collis RW, Sheinbein D, Shope C, et al
    Pediatric Allergic Contact Dermatitis Registry Patch Testing Results from 2016-2022: A Retrospective Study of Age-Related Differences.
    J Am Acad Dermatol. 2023 Jan 19:S0190-9622(23)00086.
    >> Share

  106. SIDBURY R, Alikhan A, Bercovitch L, Cohen DE, et al
    Guidelines of care for the management of atopic dermatitis in adults with topical therapies.
    J Am Acad Dermatol. 2023 Jan 11:S0190-9622(23)00004.
    >> Share

  107. SIDBURY R, Alikhan A, Bercovitch L, Cohen DE, et al
    Executive Summary: American Academy of Dermatology Guidelines of care for the management of atopic dermatitis in adults with topical therapies.
    J Am Acad Dermatol. 2023 Jan 6:S0190-9622(23)00056.
    >> Share

  108. KESKITALO PL, Jokelainen J, Tasanen K, Sinikumpu SP, et al
    Juvenile idiopathic arthritis in children and adolescents with atopic dermatitis: A Finnish nationwide registry study.
    J Am Acad Dermatol. 2023 Jan 3:S0190-9622(22)03316.
    >> Share

  109. HAGHANI DOGAHE Z, Ghorbani A, Hallaj S, Mobayen M, et al
    Modified Score of Toxic Epidermal Necrolysis to predict toxic epidermal necrolysis mortality.
    J Am Acad Dermatol. 2023;88:254-255.
    >> Share

  110. MOSTOW E
    JAAD Game Changers *: A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis.
    J Am Acad Dermatol. 2023;88:269.
    >> Share

    December 2022
  111. LIMMER EE, Knowles A, Deng J, Parthasarathy V, et al
    Atopic Dermatitis is Associated with an Increased Risk of Keloids: A Case-Control Study.
    J Am Acad Dermatol. 2022 Dec 15:S0190-9622(22)03302.
    >> Share

  112. ABUABARA K, Eichenfield LF, Bissonnette R, Silverberg JI, et al
    Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.
    J Am Acad Dermatol. 2022 Dec 12:S0190-9622(22)02792.
    >> Share

  113. BECK LA, Bieber T, Weidinger S, Tauber M, et al
    Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.
    J Am Acad Dermatol. 2022 Dec 3:S0190-9622(22)03150.
    >> Share

  114. SHTAYNBERGER B, Zippin JH
    The impact of cancer history on the prevalence of type IV hypersensitivity: A nine-year matched retrospective cohort study.
    J Am Acad Dermatol. 2022 Dec 1:S0190-9622(22)03151.
    >> Share

  115. QIAN MF, Li S, Honari G, Sarin KY, et al
    Sociodemographic disparities in patch testing for commercially insured patients with dermatitis: A retrospective analysis of administrative claims data.
    J Am Acad Dermatol. 2022;87:1411-1413.
    >> Share

  116. PARK SK, Kim JS, Seo HM
    Exposure to air pollution and incidence of atopic dermatitis in the general population: A national population-based retrospective cohort study.
    J Am Acad Dermatol. 2022;87:1321-1327.
    >> Share

    November 2022
  117. PAPP K, Szepietowski JC, Kircik L, Toth D, et al
    Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies.
    J Am Acad Dermatol. 2022 Nov 26:S0190-9622(22)03136.
    >> Share

  118. XIONG M, Warshaw EM
    Popular Sunscreens Marketed to Individuals with Skin of Color: Cost, Marketing Claims, and Allergenic Ingredients.
    J Am Acad Dermatol. 2022 Nov 14. pii: S0190-9622(22)03006.
    >> Share

  119. HEYMANN WR
    Eczema knowledge gaps: Patching things up.
    J Am Acad Dermatol. 2022;87:987-988.
    >> Share

  120. SILVERBERG JI, Patel N, Warshaw EM, DeKoven JG, et al
    Hand and foot dermatitis in patients referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2001-2018.
    J Am Acad Dermatol. 2022;87:1049-1059.
    >> Share

  121. WARSHAW EM, Xiong M, Atwater AR, DeKoven JG, et al
    Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018.
    J Am Acad Dermatol. 2022;87:1033-1041.
    >> Share

  122. JIANG Q, Ruan JW, Niu MM, Fan GZ, et al
    A predictive system for Henoch-Schonlein purpura nephritis established by multivariate analysis plus nomogram model in Chinese hospitalized children: A retrospective cohort study.
    J Am Acad Dermatol. 2022;87:1137-1139.
    >> Share

  123. WARSHAW EM, Ruggiero JL, DeKoven JG, Pratt MD, et al
    Patch testing with ammonium persulfate: The North American Contact Dermatitis Group Experience, 2015-2018.
    J Am Acad Dermatol. 2022;87:1014-1023.
    >> Share

  124. LISZEWSKI W, Zaidi AJ, Fournier E, Scheman A, et al
    Review of aluminum, paraben, and sulfate product disclaimers on personal care products.
    J Am Acad Dermatol. 2022;87:1081-1086.
    >> Share

  125. NORRESLET LB, Edslev SM, Clausen ML, Flachs EM, et al
    Hand eczema and temporal variation of Staphylococcus aureus clonal complexes: A prospective observational study.
    J Am Acad Dermatol. 2022;87:1006-1013.
    >> Share

  126. RUTHERFORD A, Glass DA 2nd, Savory S
    Dermatology in orbit: Anticipating skin care requirements in the space age.
    J Am Acad Dermatol. 2022;87:1223-1224.
    >> Share

    October 2022
  127. GORI N, Chiricozzi A, Peris K
    Response to Narla S et al.'s "Management of inadequate response and adverse effects to dupilumab in atopic dermatitis"."
    J Am Acad Dermatol. 2022 Oct 22. pii: S0190-9622(22)02967.
    >> Share

  128. VANLERBERGHE J, Dezoteux F, Martin C, Jachiet M, et al
    Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort.
    J Am Acad Dermatol. 2022 Oct 21. pii: S0190-9622(22)02960.
    >> Share

  129. SMITH B, Collier MR, Devjani S, Han G, et al
    Association between atopic dermatitis and thyroid disease among United States adults in the 2001-2006 National Health and Nutrition Examination Survey.
    J Am Acad Dermatol. 2022 Oct 13. pii: S0190-9622(22)02888.
    >> Share

  130. SLOAN B
    This month in JAAD Case Reports: October 2022. Pseudochromhidrosis and Dupilumab.
    J Am Acad Dermatol. 2022;87:750.
    >> Share

    September 2022
  131. YANG AF, San Chun K, Yu L, Walter JR, et al
    Validation of a hand-mounted wearable sensor for scratching movements in adults with atopic dermatitis.
    J Am Acad Dermatol. 2022 Sep 22. pii: S0190-9622(22)02775.
    >> Share

  132. FAN R, Leasure AC, Damsky W, Cohen JM, et al
    Alcohol use disorder among adults with atopic dermatitis: A case-control study in the All of Us research program.
    J Am Acad Dermatol. 2022 Sep 21. pii: S0190-9622(22)02739.
    >> Share

  133. BLAUVELT A, Szepietowski JC, Papp K, Simpson EL, et al
    Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream: Pooled Analysis From Two Randomized Phase 3 Studies.
    J Am Acad Dermatol. 2022 Sep 13. pii: S0190-9622(22)02688.
    >> Share

  134. HADAVAND MA, Kaffenberger B, Cartron AM, Trinidad JCL, et al
    Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis.
    J Am Acad Dermatol. 2022;87:632-639.
    >> Share

    August 2022
  135. JELOUSI S, Murase EM, Bai H, Botto NB, et al
    First, Do No Harm: The Urgent Need for Comprehensive Clinical Guidelines for Diagnostic Testing of Recalcitrant "Atopic Dermatitis".
    J Am Acad Dermatol. 2022 Aug 22. pii: S0190-9622(22)02404.
    >> Share

  136. KAMATH S
    JAAD Game Changers: Longitudinal atopic dermatitis control and persistence vary with timing of disease onset in children: A cohort study.
    J Am Acad Dermatol. 2022 Aug 3. pii: S0190-9622(22)02421.
    >> Share

  137. MAGYARI A, Ye M, Margolis DJ, McCulloch CE, et al
    Adult atopic eczema and the risk of dementia: A population-based cohort study.
    J Am Acad Dermatol. 2022;87:314-322.
    >> Share

  138. ADELANWA A, Yousaf A, Fang W, Kolodney MS, et al
    Common filaggrin gene loss-of-function variants are associated with skin cancer risk.
    J Am Acad Dermatol. 2022;87:458-460.
    >> Share

  139. FOSCHI CM, Tam I, Schalock PC, Yu J, et al
    Patch testing results in skin of color: A retrospective review from the Massachusetts General Hospital contact dermatitis clinic.
    J Am Acad Dermatol. 2022;87:452-454.
    >> Share

  140. HAN JJ, Creadore A, Seminario-Vidal L, Micheletti R, et al
    Medical management of Stevens-Johnson syndrome/toxic epidermal necrolysis among North American dermatologists.
    J Am Acad Dermatol. 2022;87:429-431.
    >> Share

    July 2022
  141. GEIER J, Schubert S, Buhl T
    Glutaraldehyde sensitization does not explain reactivity to alkyl polyglucosides in personal care products: results from review of a large contact allergy database.
    J Am Acad Dermatol. 2022 Jul 20. pii: S0190-9622(22)02399.
    >> Share

  142. BLAUVELT A, Langley RG, Lacour JP, Toth D, et al
    Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.
    J Am Acad Dermatol. 2022 Jul 18. pii: S0190-9622(22)02345.
    >> Share

  143. BRONIN A
    Emollients in infancy to prevent atopic dermatitis: A systematic review and meta-analysis.
    J Am Acad Dermatol. 2022 Jul 14. pii: S0190-9622(22)02263.
    >> Share

  144. O'CONNELL KA, Kim LS, Szeto MD, Sivesind T, et al
    From the Cochrane Library: Phototherapy for atopic eczema.
    J Am Acad Dermatol. 2022;87:e23-e26.
    >> Share

    June 2022
  145. SHETH AP, Blumstein AJ, Rangel S, Jackson KL, et al
    Three-Question Skindex-Mini Measures Quality of Life in Children with Atopic Dermatitis.
    J Am Acad Dermatol. 2022 Jun 23. pii: S0190-9622(22)02215.
    >> Share

  146. MENDES-BASTOS P, Ladizinski B, Guttman-Yassky E, Jiang P, et al
    Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of three phase 3 randomized, double-blind, placebo-controlled trials.
    J Am Acad Dermatol. 2022 Jun 14. pii: S0190-9622(22)00996.
    >> Share

  147. MOSCA M, Hadeler E, Hong J, Hakimi M, et al
    A cross-sectional study of ethnic and racial disparities in pediatric atopic dermatitis clinical trials.
    J Am Acad Dermatol. 2022 Jun 8. pii: S0190-9622(22)00908.
    >> Share

  148. AMORNRUK N, Siranart N, Sittiwattanawong P, Kueanjinda P, et al
    The immediate patch test reaction to fragrance in patients with allergic contact dermatitis to fragrance: A prospective study.
    J Am Acad Dermatol. 2022 Jun 8. pii: S0190-9622(22)00897.
    >> Share

  149. AO S, Gao X, Zhan J, Ai L, et al
    Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients.
    J Am Acad Dermatol. 2022;86:1236-1245.
    >> Share

    May 2022
  150. CHATRATH S, Lei D, Yousaf M, Chavda R, et al
    Longitudinal course and predictors of depressive symptoms in atopic dermatitis.
    J Am Acad Dermatol. 2022 May 9. pii: S0190-9622(22)00792.
    >> Share

  151. DE DR, Seivright J, Yee D, Hsiao JL, et al
    Readability, quality, and timeliness of patient online health resources for urticaria.
    J Am Acad Dermatol. 2022;86:1182-1185.
    >> Share

    April 2022
  152. SILVERBERG JI, Rangel SM, Sheth A, Blumstein A, et al
    Single-question parent-reported global atopic dermatitis severity: a valid instrument in children.
    J Am Acad Dermatol. 2022 Apr 27. pii: S0190-9622(22)00706.
    >> Share

  153. RICK JW, Morgan A, De DR, Hsiao JL, et al
    Allergens and Marketing Claims of The Most Popular Baby Moisturizers: A Product Analysis.
    J Am Acad Dermatol. 2022 Apr 26. pii: S0190-9622(22)00700.
    >> Share

  154. SHI VY, Bhutani T, Fonacier L, Deleuran M, et al
    Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND).
    J Am Acad Dermatol. 2022 Apr 16. pii: S0190-9622(22)00608.
    >> Share

  155. JELOUSI S, Butler DC
    Sleep Disturbances in Older Adults with Pruritic Eruptions: Implications Across Inconsistent Literature and a Commentary on "Association of Sleep Disturbances with Geriatric Age in Atopic Dermatitis Patients".
    J Am Acad Dermatol. 2022 Apr 11. pii: S0190-9622(22)00605.
    >> Share

  156. HEYMANN WR
    More than Mycoplasma-induced rash and mucositis: The potential role of Mycoplasma pneumoniae in Stevens-Johnson syndrome/toxic epidermal necrolysis.
    J Am Acad Dermatol. 2022;86:746-747.
    >> Share

  157. SILVERBERG JI, Hou A, Warshaw EM, DeKoven JG, et al
    Age-related differences in patch testing results among children: Analysis of North American Contact Dermatitis Group Data, 2001-2018.
    J Am Acad Dermatol. 2022;86:818-826.
    >> Share

  158. LIEW YCC, Choo KJL, Oh CC, Pang SM, et al
    Mycoplasma-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: Case-control analysis of a cohort managed in a specialized center.
    J Am Acad Dermatol. 2022;86:811-817.
    >> Share

  159. DEKOVEN JG, DeKoven BM, Warshaw EM, Mathias CGT, et al
    Occupational contact dermatitis: Retrospective analysis of North American Contact Dermatitis Group Data, 2001 to 2016.
    J Am Acad Dermatol. 2022;86:782-790.
    >> Share

  160. KOLITZ E, Karbhari N, Son T, Dominguez AR, et al
    Validation of two predictive models designed to aid clinicians in identifying Stevens-Johnson syndrome/toxic epidermal necrolysis: A single institution retrospective review.
    J Am Acad Dermatol. 2022;86:960-962.
    >> Share

  161. UGWU N, Cheraghlou S, Feng H, Cohen JM, et al
    Characterization of outpatient visits and treatments for urticaria in the United States adult population between 1998 and 2016.
    J Am Acad Dermatol. 2022;86:936-938.
    >> Share

    March 2022
  162. CHEN J, Cheng J, Yang H, Tu W, et al
    The Efficacy and Safety of Janus Kinase Inhibitors in Patients with Atopic Dermatitis: A Systematic Review and Meta-analysis.
    J Am Acad Dermatol. 2022 Mar 28. pii: S0190-9622(22)00529.
    >> Share

  163. FAN R, Leasure AC, Damsky W, Cohen JM, et al
    Association of Atopic Dermatitis with Attention Deficit Hyperactivity Disorder among US Adults in the All of Us Research Program: A Case-Control Study.
    J Am Acad Dermatol. 2022 Mar 10. pii: S0190-9622(22)00395.
    >> Share

  164. JU T, Labib A, Does AV, Yosipovitch G, et al
    Topical JAK-STAT inhibitor tofacitinib is effective in reducing non-atopic dermatitis chronic itch: a case series.
    J Am Acad Dermatol. 2022 Mar 9. pii: S0190-9622(22)00393.
    >> Share

  165. LIM JH, Lew BL, Sim WY, Kwon SH, et al
    Incidence of childhood-onset vitiligo and increased risk of atopic dermatitis, autoimmune diseases, and psoriasis: A nationwide population-based study.
    J Am Acad Dermatol. 2022 Mar 8. pii: S0190-9622(22)00390.
    >> Share

  166. KANTOR J
    This Month in JAAD International: May 2022: Atopic dermatitis severity and mental health.
    J Am Acad Dermatol. 2022 Mar 5. pii: S0190-9622(22)00368.
    >> Share

  167. SREEKANTASWAMY SA, Tully J, Edelman LS, Supiano MA, et al
    The Underrepresentation of Older Adults in Clinical Trials for JAK Inhibitors to Treat Atopic Dermatitis.
    J Am Acad Dermatol. 2022 Mar 1. pii: S0190-9622(22)00365.
    >> Share

  168. YANG CY, Chen SP, Wei JC
    Correspondence to "Association between psoriasis and asthma among United States adults in the 2009-2014 national health and nutrition examination survey".
    J Am Acad Dermatol. 2022;86:e117.
    >> Share

  169. MARTIN A, Thatiparthi A, Liu J, Ge S, et al
    Reply to "Correspondence to 'Association between psoriasis and asthma among United States adults in the 2009-2014 National Health and Nutrition Examination Survey'".
    J Am Acad Dermatol. 2022;86:e119-e120.
    >> Share

  170. MARTIN A, Thatiparthi A, Liu J, Ge S, et al
    Association between psoriasis and asthma among United States adults in the 2009-2014 National Health and Nutrition Examination Survey.
    J Am Acad Dermatol. 2022;86:709-712.
    >> Share

  171. WONGVIBULSIN S, Pahalyants V, Kalinich M, Murphy W, et al
    Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
    J Am Acad Dermatol. 2022;86:563-572.
    >> Share

  172. PATEL S, Cadwell JB, Lambert WC
    Effect of older age on complications and mortality in inpatients with Stevens-Johnson syndrome or toxic epidermal necrolysis.
    J Am Acad Dermatol. 2022;86:665-667.
    >> Share

    February 2022
  173. ZHENG DX, Cwalina TB, Jella TK, Cullison CR, et al
    Financial insecurity among U.S. children with atopic dermatitis.
    J Am Acad Dermatol. 2022 Feb 28. pii: S0190-9622(22)00362.
    >> Share

  174. DEL POZO DV, Zhu Y, Mitra N, Hoffstad OJ, et al
    The risk of atopic comorbidities and atopic march progression among Black and White children with mild to moderate atopic dermatitis: a cross-sectional study.
    J Am Acad Dermatol. 2022 Feb 19. pii: S0190-9622(22)00334.
    >> Share

  175. CHOVATIYA R, Silverberg JI
    Evaluating the Longitudinal Course of Atopic Dermatitis: a review of the literature.
    J Am Acad Dermatol. 2022 Feb 9. pii: S0190-9622(22)00253.
    >> Share

  176. THERIANOU A, Vincenzi C, Tosti A
    How safe is prescribing oral minoxidil in patients allergic to topical minoxidil?
    J Am Acad Dermatol. 2022;86:429-431.
    >> Share

    January 2022
  177. DAVIS DMR, Drucker AM, Alikhan A, Bercovitch L, et al
    AAD Guidelines: awareness of comorbidities associated with atopic dermatitis in adults.
    J Am Acad Dermatol. 2022 Jan 24. pii: S0190-9622(22)00080.
    >> Share

  178. PALLER AS, Guttman-Yassky E, Schuttelaar MLA, Irvine AD, et al
    Disease Characteristics, Comorbidities, Treatment Patterns and Quality of Life Impact in Children <12 Years Old with Atopic Dermatitis: Interim Results from the PEDISTAD Real-World Registry.
    J Am Acad Dermatol. 2022 Jan 23. pii: S0190-9622(22)00092.
    >> Share

    December 2021
  179. GAU SY
    Antibiotic Exposures Could Lead to Overestimation of Incident Outcomes-a Commentary on "Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: real-world evidence."
    J Am Acad Dermatol. 2021 Dec 20. pii: S0190-9622(21)02992.
    >> Share

  180. DAL BELLO G, Maurelli M, Schena D, Gisondi P, et al
    Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle.
    J Am Acad Dermatol. 2021 Dec 14. pii: S0190-9622(21)02975.
    >> Share

  181. ATWATER AR, Bembry R, Liu B, Warshaw EM, et al
    Medical Adhesive Allergens: Retrospective Analysis of Cross-Sectional Data from the North American Contact Dermatitis Group, 2001-2018.
    J Am Acad Dermatol. 2021 Dec 4. pii: S0190-9622(21)02927.
    >> Share

  182. COIFFARD LJM, Couteau C
    Are alkyl glucosides really allergens?
    J Am Acad Dermatol. 2021;85:e355.
    >> Share

  183. MUFTI A, Sachdeva M, Kim P, Rahat S, et al
    A systematic review of eczematous eruptions in patients receiving biologic therapy.
    J Am Acad Dermatol. 2021;85:1630-1635.
    >> Share

  184. RINOLDI PO, Bronz G, Ferrarini A, Mangas C, et al
    Acute hemorrhagic edema: Uncommon features.
    J Am Acad Dermatol. 2021;85:1620-1621.
    >> Share

  185. AL MUSALHI BH, Al Kamzari A, Al Kindi F, Al Abrawi S, et al
    Clinical spectrum of childhood-onset hypocomplementemic urticarial vasculitis in Oman: A retrospective multicenter study.
    J Am Acad Dermatol. 2021;85:1617-1620.
    >> Share

  186. HIROTSU KE, Rana J, Wang JY, Raghavan SS, et al
    Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
    J Am Acad Dermatol. 2021;85:1610-1611.
    >> Share

  187. MCCORMACK L, Thompson LL, Chang MS, Polyakov N, et al
    Cutaneous adverse events to immune checkpoint inhibitors in pediatric populations: A retrospective cohort study.
    J Am Acad Dermatol. 2021;85:1587-1589.
    >> Share

  188. BETTUZZI T, Ingen-Housz-Oro S, Purtillo CC, Le Cleach L, et al
    Changing spectrum of suspected drugs of epidermal necrolysis: A World Health Organization pharmacovigilance database analysis from 1997-2020.
    J Am Acad Dermatol. 2021;85:1581-1584.
    >> Share

  189. WARSHAW EM, Schlarbaum JP, Silverberg JI, DeKoven JG, et al
    Contact dermatitis to personal care products is increasing (but different!) in males and females: North American Contact Dermatitis Group data, 1996-2016.
    J Am Acad Dermatol. 2021;85:1446-1455.
    >> Share

  190. CHOVATIYA R, Silverberg JI
    Association of herpes zoster and chronic inflammatory skin disease in US inpatients.
    J Am Acad Dermatol. 2021;85:1437-1445.
    >> Share

    November 2021
  191. GUO L, Bai H, Botto N, Woodruff CM, et al
    Allergens and Marketing Claims in Commercial Hand Sanitizers: A Cross-Sectional Study.
    J Am Acad Dermatol. 2021 Nov 24. pii: S0190-9622(21)02895.
    >> Share

  192. ROH YS, Huang AH, Sutaria N, Choi U, et al
    Real-world comorbidities of atopic dermatitis in the U.S. adult ambulatory population.
    J Am Acad Dermatol. 2021 Nov 17. pii: S0190-9622(21)02838.
    >> Share

  193. CHOVATIYA R, Silverberg JI
    DESCRIBE-AD: A Novel Classification Framework for Atopic Dermatitis.
    J Am Acad Dermatol. 2021 Nov 10. pii: S0190-9622(21)02795.
    >> Share

  194. KAMEL K, Militello M, Sivesind TE, Szeto MD, et al
    From the Cochrane Library: Psychologic and educational interventions for atopic eczema in children.
    J Am Acad Dermatol. 2021;85:e309-e311.
    >> Share

  195. CHENG HM, Tey HL
    Response to: Momen et al's "Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms: Facial edema aligns to the severe phenotype".
    J Am Acad Dermatol. 2021;85:e303-e304.
    >> Share

  196. CHERAGHLOU S, Watsky KL, Cohen JM
    Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017.
    J Am Acad Dermatol. 2021;85:1218-1226.
    >> Share

    October 2021
  197. PALLER AS, Mina-Osorio P, Vekeman F, Boklage S, et al
    Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: real-world evidence.
    J Am Acad Dermatol. 2021 Oct 28. pii: S0190-9622(21)02720.
    >> Share

  198. SAEKI H, Ito K, Yokota D, Tsubouchi H, et al
    Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized double-blind vehicle-controlled trial.
    J Am Acad Dermatol. 2021 Oct 25. pii: S0190-9622(21)02682.
    >> Share

  199. GHAFARI G, Liszewski W
    Comparison of the formulation and allergenic potential of "clean" and traditional shampoos.
    J Am Acad Dermatol. 2021 Oct 22. pii: S0190-9622(21)02684.
    >> Share

  200. KAUPPI S, Jokelainen J, Timonen M, Tasanen K, et al
    Atopic dermatitis and the risk of eating disorders: a population-based cohort study.
    J Am Acad Dermatol. 2021 Oct 21. pii: S0190-9622(21)02674.
    >> Share

  201. RAKITA U, Kaundinya T, Silverberg JI
    Lack of association between atopic dermatitis severity and worsening during pregnancy: a cross-sectional study.
    J Am Acad Dermatol. 2021 Oct 7. pii: S0190-9622(21)02585.
    >> Share

  202. WU JJ, Martin A, Liu J, Thatiparthi A, et al
    The risk of COVID-19 infection in patients with atopic dermatitis - a retrospective cohort study.
    J Am Acad Dermatol. 2021 Oct 6. pii: S0190-9622(21)02578.
    >> Share

  203. QUACH HT, Johnson DB, LeBoeuf NR, Zwerner JP, et al
    Cutaneous adverse events caused by immune checkpoint inhibitors.
    J Am Acad Dermatol. 2021;85:956-966.
    >> Share

  204. DUPLISEA MJ, Roberson ML, Chrisco L, Strassle PD, et al
    Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis.
    J Am Acad Dermatol. 2021;85:873-877.
    >> Share

  205. CHOUDHARY R, Vinay K, Srivastava N, Bishnoi A, et al
    Clinical, biochemical, and serologic predictors of drug reaction with eosinophilia and systemic symptoms syndrome: A prospective case-control study.
    J Am Acad Dermatol. 2021;85:901-909.
    >> Share

  206. SACHDEVA M, Mufti A, Kim P, Maliyar K, et al
    Biologic treatment in pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis: A systematic review.
    J Am Acad Dermatol. 2021;85:1011-1013.
    >> Share

    September 2021
  207. SILVERBERG JI, Hou A, Warshaw EM, Maibach HI, et al
    Prevalence and Trend of Allergen Sensitization in Patients with a Diagnosis of Seborrheic Dermatitis After Patch Testing, North American Contact Dermatitis Group Data, 2001-2016.
    J Am Acad Dermatol. 2021 Sep 25. pii: S0190-9622(21)02522.
    >> Share

  208. MOLOGOUSIS M, Goldminz AM
    References for Common Contact Allergens Present in Prescription Topical Corticosteroids.
    J Am Acad Dermatol. 2021 Sep 24. pii: S0190-9622(21)02490.
    >> Share

  209. HUGHES ME, Aralis H, Bruhn KW, Cotliar J, et al
    A reliability study using Network-Oriented Research Assistant to evaluate the use of digital photographs in the assessment of atopic dermatitis.
    J Am Acad Dermatol. 2021;85:725-726.
    >> Share

  210. WALDMAN RA, DeWane ME, Sloan SB, King B, et al
    Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: A multi-institution retrospective chart review.
    J Am Acad Dermatol. 2021;85:735-736.
    >> Share

  211. MOMEN SE, Diaz-Cano S, Walsh S, Creamer D, et al
    Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms: Facial edema aligns to the severe phenotype.
    J Am Acad Dermatol. 2021;85:645-652.
    >> Share

    September 2020
  212. LYTVYN Y, Mufti A, Sachdeva M, Maliyar K, et al
    Stevens Johnson Syndrome and Toxic Epidermal Necrolysis Reactions to BRAF and MEK Inhibitors in Patients with Melanoma: A Systematic Review.
    J Am Acad Dermatol. 2020 Sep 11. pii: S0190-9622(20)32613.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016